IDEXX Laboratories Inc
NASDAQ:IDXX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
406.92
576.87
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
IDEXX Laboratories Inc
IDEXX Laboratories Inc
Accrued Liabilities
IDEXX Laboratories Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Accrued Liabilities
$511m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Accrued Liabilities
$2.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Stryker Corp
NYSE:SYK
|
Accrued Liabilities
$3.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Accrued Liabilities
$6.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Accrued Liabilities
$867.5m
|
CAGR 3-Years
21%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
IDEXX Laboratories Inc
Glance View
IDEXX Laboratories Inc. is a leading global provider of veterinary diagnostic products and services, dedicated to enhancing the health and well-being of pets worldwide. Founded in 1983, the company has established itself as an innovator in the animal healthcare market, offering a comprehensive range of diagnostic tests, equipment, and software that empower veterinarians to make informed decisions. With a consistent focus on research and development, IDEXX has expanded its portfolio to include cutting-edge solutions such as digital imaging and telemedicine, addressing the growing needs of the pet care industry. Their strategic partnerships and robust distribution channels further bolster their presence in both developed and emerging markets. For investors, IDEXX represents a compelling opportunity within a steadily growing sector. The company's recurring revenue model, driven by its suite of diagnostic tests and subscriptions to software solutions, ensures stable cash flow and predictability in earnings. IDEXX has also demonstrated impressive financial performance, characterized by strong revenue growth, high profit margins, and a commitment to shareholder returns. By harnessing trends in pet ownership and increasing expenditures on pet healthcare, IDEXX positions itself as a reliable player in the marketplace. With its dedication to innovation, customer service, and global expansion, IDEXX Laboratories Inc. stands poised for sustained growth, making it an attractive consideration for long-term investors.
See Also
What is IDEXX Laboratories Inc's Accrued Liabilities?
Accrued Liabilities
511m
USD
Based on the financial report for Sep 30, 2024, IDEXX Laboratories Inc's Accrued Liabilities amounts to 511m USD.
What is IDEXX Laboratories Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
13%
Over the last year, the Accrued Liabilities growth was 38%. The average annual Accrued Liabilities growth rates for IDEXX Laboratories Inc have been 10% over the past three years , 15% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
